Retogatein (rhGAD65/alum)
Stage 3 Type 1 Diabetes (recent-onset)
Key Facts
About Diamyd Medical
Diamyd Medical is a clinical-stage biotech focused on developing disease-modifying therapies for type 1 diabetes (T1D). Its core strategy centers on antigen-specific immunotherapy using its proprietary recombinant GAD65 antigen, delivered intralymphatically to induce immune tolerance. The company has achieved significant milestones including Fast Track and Orphan Drug Designations from the FDA, full enrollment in its Phase 3 DIAGNODE-3 trial, and the establishment of a dedicated manufacturing facility. Diamyd's precision medicine approach aims to halt autoimmune destruction and preserve endogenous insulin production, potentially transforming T1D management.
View full company profileAbout Diamyd Medical
Diamyd Medical is a clinical-stage biotech focused on developing disease-modifying therapies for type 1 diabetes (T1D). Its core strategy centers on antigen-specific immunotherapy using its proprietary recombinant GAD65 antigen, delivered intralymphatically to induce immune tolerance. The company has achieved significant milestones including Fast Track and Orphan Drug Designations from the FDA, full enrollment in its Phase 3 DIAGNODE-3 trial, and the establishment of a dedicated manufacturing facility. Diamyd's precision medicine approach aims to halt autoimmune destruction and preserve endogenous insulin production, potentially transforming T1D management.
View full company profile